Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Militello AM, Orsi G, Cavaliere A, Niger M, Avallone A, Salvatore L, Tortora G, Rapposelli IG, Giordano G, Noventa S, Giommoni E, Bozzarelli S, Macchini M, Peretti U, Procaccio L, Puccini A, Cascinu S, Montagna C, Milella M, Reni M. Militello AM, et al. Among authors: peretti u. Cancer Chemother Pharmacol. 2023 Dec;92(6):501-510. doi: 10.1007/s00280-023-04585-w. Epub 2023 Sep 19. Cancer Chemother Pharmacol. 2023. PMID: 37725113
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients.
Macchini M, Peretti U, Orsi G, Zanon S, Mazza E, Valente MM, Tamburrino D, Belfiori G, Rossi G, Testoni SGG, Passoni P, Doglioni C, Cascinu S, Reni M. Macchini M, et al. Among authors: peretti u. Cancer Chemother Pharmacol. 2021 Jan;87(1):95-101. doi: 10.1007/s00280-020-04190-1. Epub 2020 Nov 6. Cancer Chemother Pharmacol. 2021. PMID: 33159215
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Orsi G, Cavaliere A, Tortora G, Lonardi S, Macchini M, Di Marco M, Giordano G, Vasile E, Scartozzi M, Bozzarelli S, Noventa S, Rodriquenz MG, Militello AM, Rapposelli IG, Garajova I, De Lorenzo S, Merelli B, Bittoni A, Salvatore L, Procaccio L, Paratore C, Spallanzani A, Peretti U, Niger M, Giommoni E, Bernardini I, Tamburini E, Bernardino K, Forti L, Valente MM, Cascinu S, Milella M, Reni M. Orsi G, et al. Among authors: peretti u. Br J Cancer. 2023 Mar;128(5):877-885. doi: 10.1038/s41416-022-02086-w. Epub 2022 Dec 8. Br J Cancer. 2023. PMID: 36482190 Free PMC article.
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.
Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquenz MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, Melisi D, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M. Peretti U, et al. ESMO Open. 2021 Feb;6(1):100032. doi: 10.1016/j.esmoop.2020.100032. Epub 2021 Jan 4. ESMO Open. 2021. PMID: 33399070 Free PMC article.
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M. Orsi G, et al. Among authors: peretti u. ESMO Open. 2021 Oct;6(5):100238. doi: 10.1016/j.esmoop.2021.100238. Epub 2021 Aug 13. ESMO Open. 2021. PMID: 34392104 Free PMC article.
29 results